| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8680604 | Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2017 | 11 Pages |
Abstract
The UBITh® platform can generate a high-precision molecular vaccine with high responder rate, strong on-target immunogenicity, and a potential of cognition improvement, which support UB-311 for active immunotherapy in early-to-mild AD patients currently enrolled in a phase-II trial (NCT02551809).
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Chang Yi Wang, Pei-Ning Wang, Ming-Jang Chiu, Connie L. Finstad, Feng Lin, Shugene Lynn, Yuan-Hung Tai, Xin De Fang, Kesheng Zhao, Chung-Ho Hung, Yiting Tseng, Wen-Jiun Peng, Jason Wang, Chih-Chieh Yu, Be-Sheng Kuo, Paul A. Frohna,